Document is current
Any future updates will be listed below
-
Authors
Glassock, Richard J. https://orcid.org/0000-0003-4115-3647
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Received: 7 January 2025
Accepted: 20 March 2025
First Online: 12 April 2025
Declarations
:
: Richard J. Glassock is a compensated consultant for Alexion, Alpine, Arrowhead, BioCryst, Chinook, Equillium, Horizon, Immunovant, Ionis, Mironid, Nkarta, Novartis, Omeros, Orange Grove Bio, RenaSight (Natera), River3Renal, Travere, Vera, Zydus, and Zversa; he also receives a stipend from Wolters Kluwer and Karger for editorial services.
: This article is based on author opinion and previously conducted studies and does not contain any new studies with human participants or animals performed by the author.
